Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Bob Ramsey of Kantar Health addresses the complexity of forecasting oncology products. The oncology market is facing new trends and therapies that present great opportunities for the future of pharma.

Jim Furniss and Chris Teale discuss the market access environment for new oncology products in Europe, including sales comparisons with the US and their thoughts on the future. What do we mean by ...

"As we advance our broader strategy to build a leading injectables portfolio with durable, high-impact complex products, we are excited to announce the U.S. launch of Boruzu in our oncology portfolio.

Predictive Oncology shares are trading higher on Tuesday after the company announced it developed predictive models to target ...

Limited (LON:HCM – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 258.58 ($3.34) and traded as low as GBX 231 ($2.98) ...

with a proven track record of driving revenue growth and expanding market presence for various oncology products. He has held senior positions at major pharmaceutical companies like Bayer ...

Kanvas Biosciences’ new research suggests that the company’s HiPR-Map Platform is capable of outperforming traditional ...